NCHR Comments on Hormone Therapy in Postmenopausal Women for the Primary Prevention of Chronic Conditions

May 16, 2022. The currently available evidence on hormone therapy is very clear: Whether combination therapies of estrogen and progestin or treatments with estrogen alone, the risks by far outweigh the limited benefits for postmenopausal women. We thus strongly support USPSTF’s “D” grade recommendation against the use of combined estrogen and progestin for the primary prevention of chronic conditions such as cardiovascular disease, types of cancer, and osteoporotic fractures in postmenopausal persons, as well as the “D” grade recommendation against the use of estrogen alone in postmenopausal persons who have had a hysterectomy.

Read More »

Menopause and Hormones

There are serious risks as well as benefits of taking hormones for menopause. Although the FDA plans to delete most of the Black Box warnings, that doesn’t mean hormones are safe. We make this complex issue as simple as possible. Bottom line: Hormone creams for vaginal dryness are safer than hormone pills or patches.

Read More »